Medical Letter on the CDC & FDA
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC & FDA
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Diagnostics
AtherOx launched to identify risk for atherosclerotic cardiovascular disease
October 23rd, 2005
Corgenix Medical Corp. (CONX), a worldwide marketer of diagnostic test kits, announced the launch of AtherOx, a product line utilizing patented technology to identify individuals at risk for developing atherosclerotic cardiovascular disease. The AtherOx technology is a diagnostic product that measures oxidized low-density lipoprotein complexed with a plasma protein known as B2GP1, which combined functions as a specific marker of potential cardiovascular disease. While increased levels of the AtherOx complex have been found to be a risk factor for accelerated cardiovascular disease, increased levels of antibodies to AtherOx indicate progression of...
Source: Medical Letter on the CDC & FDA (2005-10-23)
|
